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1. Introduction  
Hemophilia, a common congenital coagulation disorder, is classified as hemophilia A (HA) 
and hemophilia B (HB), which result from a deficiency or dysfunction of coagulation factor 
VIII (FVIII) and factor IX (FIX), respectively. HA is known to be caused by heterogeneous 
mutations of the FVIII gene (F8), such as inversions, substitutions, deletions, insertions, etc. 
F8 (NM_000132.3) is located on the long arm of the Xq28 region of the X chromosome. F8 is 
extremely large (186 kb) and consists of 26 exons (Graw et al., 2005). The transcript of F8 is 
approximately 9010 bp and comprises a short 5′-untranslated region (5′-UTR; 150 bp), an 
open reading frame (ORF) plus stop codon (7056 bp), and a long 3′-UTR (1806 bp). The 
protein product of F8 is a cofactor of FIX, without enzyme activity. The ORF encodes a 
signal peptide with 19 amino acids at its N-terminus, which leads to the passage of FVIII 
through hepatocytes to blood vessels. The matured FVIII protein contains 2332 amino acids 
and a glycoprotein of approximately 250 kDa, and circulates as an inactive pro-cofactor. 
FVIII is a multi-domain protein composed of A1-A2-B-A3-C1-C2, named from the N-
terminus. FVIII synthesized in hepatocytes is secreted into the circulation and readily 
assembled with von Willebrand factor (vWF), which is generated and secreted by 
endothelial cells. Besides vWF, FVIII protein can also interact with diverse proteins such as 
thrombin and FX. These interactions are important for effective hemostasis. However, F8 
mutations can lead to the production of truncated proteins, which lead to disruption of 
FVIII function and suppress normal protein interaction with proteins involved in the 
coagulation cascade (Bowen, 2002). This inappropriate reaction causes bleeding tendency.  
F8 mutations can occur at diverse sites in a variety of types, such as structural variation 
(inversions of intron 22 or intron 1) and sequence variation (insertion, deletion, and 
substitution). The latter variation leads to nonsense, missense, and frameshift mutations. 
Recently, more than 1,200 types of F8 mutations were reported in the HAMSTeRS 
(Hemophilia A Mutation, Structure, Test and Resource Site) database (http://hadb.org.uk). 
The F9 gene (NM_000133.3) is also located on the X chromosome at Xq27.1–q27.2. In contrst 
to F8, the size of F9 gene is approximately 34 kb with only eight exons and the size of the 






K-dependent coagulation factors in humans. FIX is synthesized in the liver as 461 amino 
acid residues, including 46 signal peptides at its N-terminus. It circulates in the blood as a 
single-chain glycoprotein of inactive zymogen (Yoshitake et al., 1985). When coagulation is 
initiated, FIX is converted to an active form (FIXa) by proteolytic cleavage, resulting in an N-
terminal light chain and a C-terminal heavy chain held together by one or more disulfide 
bonds (Di Scipio et al., 1978; Lindquist et al., 1978). The role of FIXa in the blood coagulation 
cascade is to activate factor X through interactions with calcium ions, membrane 
phospholipids, and FVIII. 
More than 1,000 mutations have been reported for F9 to date (http://hadb.org.uk). The  
data archived in the locus-specific mutation database for F9 (http://www.kcl.ac.uk/ip/ 
petergreen/haemBdatabase.html) describe the genotype-phenotype correlations. Although 
the mutations are scattered over the entire structure of the F9 gene, the distribution of 
mutation types shows that missense/nonsense mutations are the most common, accounting 
for ~64% of mutations, followed by frameshift mutations (~17%). More than 90% of 
mutations are point mutations that can be detected by direct sequencing analyses (Mahajan 
et al., 2007). The rest (<10%) consist of large exon deletion mutations or complex 
rearrangements. Unlike in HA, mutations with large inversion rearrangement are rare in 
HB. 
2. Profiling of the F8 mutations  
The profiling of F8 mutations is important for a precise diagnosis of HA, understanding of 
genotype-phenotype correlation, carrier detection, prenatal diagnosis, and predicting 
inhibitor development. As there are various types of mutations, we propose a strategy for 
profiling F8 mutations as follows (Figure 1)  
 
 
Fig. 1. A proposed strategy for profiling of F8 mutation. 
2.1 Identification of inversions in intron 22 or intron 1 
The most common defect in F8 is intron 22 inversion, which occurs via homologous 
recombination between int22h-1 (intragenic) with int22h-2 or int22h-3 (extragenic) (Liu et al., 
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1998). Figure 2 is a schematic presentation of intron 22 inversion of F8. The incidence of 
intron 22 inversion is approximately 40~50% in severe HA patients, and without a 
significant ethnic difference (Bowen, 2002). Intron 22 inversion is also a high risk factor for 
inhibitor formation, thus, it has drawn special attention as a hotspot of F8 mutation 
(Oldenburg et al., 2000; Oldenburg et al., 2002). In a previous report, HA patients with 
intron 22 inversion exhibited an inhibitor prevalence of >22% (Boekhorst et al., 2008). For 
this reason, tests for intron 22 inversion have been the primary step of F8 mutation profiling.  
 
 
Fig. 2. Schematic presentation of the intron 22 inversion of the F8. (A) The normal structure 
of the F8 gene. Gray boxes represent exon region and upper number is exon number. White 
arrow represent intron 22 homologous region (int22h-2; proximal and int22h-3; distal region) 
and black arrow indicates int22h-1 (intragenic). (B) Homologous recombination process 
occurs between int22h-1 and int22h-2 (type 2 inversion) or int22h-3 (type 1 inversion).  
(C) The inversions induce disruption of F8 gene. Exons 1 to 22 are displaced towards the 
telomere and are oriented in a direction opposite to their normal orientation.  
Xqtel: X- chromosome q arm telomere, Xqcen: X-chromosome q arm centromere. 
Recently, the long-distance PCR (LD-PCR) method was developed for more effective 
investigation of intron 22 inversion (Liu et al., 1998; Polakova et al., 2003). LD-PCR is 
conducted with primers P, Q, A, and B in accordance with the methods of Liu et al (1998). 
Primers are designed so that primers P and Q bind to int22h-1, whereas primers A and B 
bind to int22h-2 and int22h-3 (Figures 3A and 3B). Figure 3C illustrates an LD-PCR result 
identifying a Korean HA patient with intron 22 inversion. Lanes 1, 4, and 7 indicate the 
product of the A+B primer pair (10 kb), which was amplified in both the inversion positive 
and negative patients. However, there was a difference between the B+P primer pair 
product in the intron 22 inversion and the wild type; an 11 kb product was generated only 
in the inversion patient (lanes 5 and 8) but not in the wild type (lane 2). Additionally, the 
result of the product from P+Q showed that a 12 kb band was generated only in the wild 
type (lane 3) but not in the inversion patient (lanes 6 and 9). These results demonstrate that 







Fig. 3. Primer design for LD-PCR and result of intron 22 inversion test . (A) The normal 
formation of F8 gene and intron 22 homologous region and (B) intron 22 inversion-occured 
F8 gene. Red arrows represent binding sites for the primers A, B, P and Q. Primers A and B 
hybridize to forward and rear region of int22h-2 and int22h-3. Combination of primers P and 
Q hybridize to forward and rear region of int22h-1. In the inversion-negative case, LD-PCR 
with the primers A+B will make a 10 kb PCR product and primers P+Q make a 12 kb one. 
However, primer B+P will not make any PCR product. While inversion-positive patient will 
produce a 11 kb band with the primer B+P mixture. (C) Intron 22 inversion test by LD-PCR 
to one intron 22-negative and two intron 22-positive patients. Lanes 1, 4 and 7 show the 
results of the primer A+B (product size is a 10 kb) which is amplified in both the inversion 
and non-inversion cases. Lanes 2, 5 and 8 show the product of the primer B+P mixture for 
the detection of inversion (11 kb). Lanes 3, 6 and 9 indicate the product of the P+Q primer 
mixture. M indicates size marker. 
Keeney et al (2005) recently reported that multiplex-PCR is available for carrier detection. 
The multiplex-PCR reaction for the detection of intron 22 inversion is conducted  
with primers A+B+P+Q combined in 1 tube. If a sister is a HA carrier with intron 22 
inversion, 3 bands (10 kb, 11 kb, and 12 kb) will be produced. However, if a sister does not 
have an intron 22 inversion mutation, the products will be 2 (10 kb and 12 kb) rather than  
3 bands. 
Similar to intron 22 inversion, intron 1 inversion also occurs via homologous recombination 
between int1h-1 (intragenic) and int1h-2 (extragenic) in the F8 promoter region (Bagnall et 
al., 2002). Figure 4 represents a schematic of homologous recombination in int1h-1 and int1h-
2. In the figure, homologous recombination will result in an intron 1 breaking inversion and 
induces a severe mutation. Although several studies have investigated the prevalence of 
intron 1 inversion, its prevalence remains controversial (1~5% in HA) (Schroder, J. et al., 
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2006). The importance of intron 1 inversion is also related to inhibitor formation (Fidanci et 
al., 2008; Repesse et al., 2007).  
 
 
Fig. 4. Scehmatic veiw of intron 1 inversion process. (A) Homologous region of intron 1 is 
located in the intragenic region (white arrow, int1h-1) and extragenic region (black arrow, 
int1h-2). (B) Homologous recombination occurs between int1h-1 and int1h-2. (C) The result 
of intron 1 inversion will not synthesize an appropriated FVIII protein because the direction 
of expression is changed. Xqtel: X- chromosome q arm telomere, Xqcen: X-chromosome q arm 
centromere. 
To profile F8 mutations, we investigated intron 22 inversion and exon deletion (to be 
discussed later) and then the patients without intron 22 inversion and exon deletion were 
tested for intron 1 inversion. The amplification products of int1h-1 and int1h-2 are analyzed 
with the method described by Bagnall et al (2002). For detection of intron 1 inversion, 
primers 9F, 9cF, 2F, and 2R were prepared according to the guidelines established by 
Bagnall et al (Figure 5). The mixed primers 9cR+9F+2F and 2F+2R+9F were used for the 
amplification of int1h-1 and int1h-2, respectively. The product of primers 9cR+9F+2F (int22h-
1) was expected to be a 2.0 kb band, whereas the primers 2F+2R+9F (int22h-2) were expected 
to generate a 1.2 kb product from the wild-type sample (Figure 5A). As shown in Figure 5C, 
1.4 kb and 1.8 kb amplicons were produced by the 2F+9F+9cR primers and 2F+2R+9F 
primers (lanes 1 and 2), respectively, in the case of intron 1 inversion. However, the wild 
type (inversion test negative) produced 2.0 kb and 1.2 kb PCR products (Figure 5C, lane 3 
and lane 4). 
2.2 Identification of exon deletion by multiplex-PCR method 
Although direct sequencing is a useful method for detection of sequence variation, it has been 
reported that the method is unable to detect certain gross exon deletions (El-Maarri et al., 
2005). For this reason, investigation for gross exon deletion is needed for F8 mutation profiling 
before sequence analysis can be carried out. In a previous study, we reported identifying a HA 







Fig. 5. Primer design and intron 1 inversion test. Linearised diagram of normal (A) and 
intron 1 inversion (B) of F8 gene. Red arrows indicate binding sites for each primer. (C) The 
result of intron 1 inversion test. Primer 2F+9F+9cR combination (lane 1, 3) and primer 
2F+2R+9F combination (lane 2, 4) were used for the amplifications of int1h-1 and int1h-2, 
respectively. (C) Lane 1 and 2 illustrate the product of the intron 1 inversion-positive 
patient, whereas lane 3 and 4 illustrate intron 1 inversion- negative patients. M: 1 kb  
size marker. 
detect the 26 exons of F8 (Hwang et al., 2009). In contrast to the routinely used singleplex 
PCR, which requires 35 PCR reactions per patient to detect exon deletion, only 8 PCR 
reactions were necessary when multiplex-PCR was used (Figure 6). These results 
demonstrate that multiplex-PCR is simple and useful for many PCR product analyses in 1-
tube reactions. As exon deletion tends to be associated with severe phenotypes, a detection 
method with simple and accurate application is very important. This method is easily 
applied to PCR machines and requires no special equipment such as a capillary sequencer 
for multiplex ligation-dependent probe amplification (MLPA) (Lannoy et al., 2009). 
Although the MLPA method is powerful and has its advantages, such as being free from 
primer dimerization and false priming, multiplex-PCR is still a useful method for the 
detection of exon deletion in local laboratories or in developing countries. Thus, multiplex-
PCR analysis can be used as the secondary test prior to direct sequencing. We found that the 
incidence of gross exon deletion in the Korean HA was 2.6% (Hwang et al 2009). 
2.3 Direct sequencing analysis 
Finally, direct sequencing can be applied to patients who do not have the mutations 
mentioned above. In many reports, there is no hotspot for the distribution of sequence 
variations in F8 (Bogdanova et al., 2005; Tuddenham et al., 1994). Therefore, all 26 exons, 
including splicing sites and some portions of the intron region, should be covered by  
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Fig. 6. Detection of gross exon deletion by multiplex-PCR. (A) Multiplex-PCR were 
performed with 8 primer sets. (B) Singleplex-PCR was performed with 35 primers. The 
numbers on each lane indicates the primer set (1~8) and single primer (lane 1~35). M: 100 bp 
size marker. 
sequencing analysis. One of the more useful primer sequences is the set developed by David 
et al (David et al., 1994). These primers contain approximately 20 nucleotides of intronic 
sequences flanking each exon. The mRNA sequence of F8 was used for the detection of 
mutations at splicing sites because certain splicing site mutations are not detected when 
genomic DNA material is used (Chao et al., 2003; El-Maarri et al., 2005). Conformational 
sensitive gel electrophoresis (CSGE) or denaturing gradient gel electrophoresis (DGGE) is 
applied for the detection of mutations with single or larger base mismatches (Korkko et al., 
1998). The assay is based on the assumption that a buffer containing mild denaturing 
solvents can resolve the conformational changes produced by single-base matches in 
double-strand DNA, which result in an increase of the differential migration in 
electrophoresis (Korkko et al., 1998). However, these methods are very sensitive to 
experimental conditions; thus, optimization of conditions is a difficult and time-consuming 
process. As the cost of sequencing analysis is decreasing by the day, we applied sequencing 
analysis to each PCR product with reference to the F8 sequence (NM_000132.3) and without 
mutation screening by CSGE or DGGE. The results of sequencing were analyzed with 
diverse programs such as DNASTAR, CLC workbench, and ClusteralW. We identified 
various sequence variations from Korean HA patients who did not have the mutations 
mentioned above. These mutations included 8 novel types that were not listed in the 






3. Profiling of the F9 mutation 
The identification of disease-causing mutations in the F9 gene is also critical for diagnosis, 
genotype-phenotype correlations including inhibitor risk, genetic counseling, and prenatal 
diagnosis of HB. (Mahajan et al., 2007; Tagariello et al., 2007). More than 1,000 mutations 
have been reported in the literature, and the distribution of mutation types in HB is 
somewhat different from those in HA (HGMD Professional 2010.4, release date 18 December 
2010, URL: http://www.hgmd.org/). A locus-specific mutation database also exists for HB 
(The Hemophilia B Mutation Database – version 13, last update in 2004, URL: 
http://www.kcl.ac.uk/ip/petergreen/haemBdatabase.html). Point mutations account for 
the majority of mutations (~90%) and large exon deletion mutations account for ~6%. 
Complex rearrangement mutations without exonal dosage changes (copy-neutral) have 
rarely been reported; large inversion mutations such as intron 22 inversion in HA have not 
been reported in HB. Missense/nonsense mutations account for ~70% of point mutations, 
followed by small insertion/deletion mutations (~17%). In addition, it is notable that whole 
gene deletions account for approximately half of the large exon deletion mutations in F9. 
Based on the line of evidence collected from the literature and mutation database, the 
following is a proposed procedure for profiling F9 mutations (Figure 7). 
 
 
Fig. 7. A proposed strategy of F9 mutation profiling. 
3.1 Identification of F9 point mutations by direct sequencing analysis 
As point mutations account for ~90% of cases, direct sequencing can be the first-line 
diagnostic modality for molecular diagnosis in HB. As in HA, the mutations are scattered 
throughout the gene, thus, sequencing analyses need to cover the coding sequences and 
flanking intronic sequences of all 8 exons (Kwon et al., 2008). The strategy for direct 
sequencing analysis is largely similar to that for HA, but is simpler and less costly because 
the F9 gene is smaller and is encoded by a smaller number of exons. In addition, as in HA, 
mutation scanning by CSGE can also be applied for direct sequencing analyses, but the 
detection sensitivity of CSGE needs to be validated in each laboratory prior to clinical 
implementation (Santacroce et al., 2008). Large deletion mutations, which can be detected by 
MLPA analyses, should be suspected when 1 or more reactions to amplify a genomic 
segment fail. Below is an example of a sequencing result with a missense mutation in a 
Korean HB (Kwon et al., 2008). 
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Fig. 8. A point mutation (missense mutation) leading to the substituion of the 64th amino 
acid residue cysteine to arginine detected by direct sequencing analyses in a Korean male 
patient with HB 
3.2 Identification of large exon deletion mutations by multiplex ligation-dependent 
probe amplification 
The possibility of large exon deletion mutations should be considered (second-line 
molecular genetic test in HB) when no point mutations are identified through direct 
sequencing analyses or when PCR experiments fail on 1 or more exons. As in HA, the 
MLPA technique is a robust molecular test to detect mutations of large exon deletion 
affecting 1 or more exons in F9 (Kwon et al., 2008). The principle and method of 
interpretation of MLPA results are similar to that for F8. The detection of this type of 
mutation is particularly important since it implicates a high risk of inhibitor development 
(Giannelli et al., 1983; Oldenburg et al., 2004). The real-time quantitative PCR technique can 
also be used to detect large exon deletion mutations in F9 (Vencesla et al., 2007). However, 
recent studies have pointed out the advantages of MLPA over real-time PCR (Casana et al., 
2009). Figure 9 is an example of a result of a multiplex ligation-dependent probe 
amplification experiment with whole gene deletion in a Korean male HB. 
3.3 Identification of large rearrangement mutations without large exon  
deletion changes 
The need to search for copy-neutral large rearrangement mutations arises when no point 
mutations or large exon deletion mutations are detected on direct sequencing followed by 
MLPA analyses. In particular, a balanced chromosomal rearrangement involving the F9 
gene on the Xq27.1 band disrupts the normal transcription and translation of the molecule, 
leading to HB. Karyotype analyses using peripheral blood lymphocytes can detect 
rearrangements such as t(X;1)(q27.1;q22 or q23) and t(X;15)(q27.1;p11.2) (Ghosh et al., 2009; 
Schroder, W. et al., 1998). In particular, these rearrangements can be the genetic 
backgrounds of female HB with or without family history. X chromosome analyses are 








Fig. 9. The chromatographic results of the multiplex ligation-dependent probe amplificaiton 
experiment showing the whole F9 gene deletion in a male patient with haemophilia B 
4. New approach of the mutation profiling 
Technologies for more efficient detection of mutations such as microarrays and next 
generation sequencing (NGS) have been developed. Although mutation testing with 
microarrays has received attention, it faces limitations in identifying various mutations 
(Berber et al., 2006; Chan et al., 2005). In addition, microarray-identified mutations require 
validation to eliminate false positive or false negative results (Johnson et al., 2010). On that 
point, NGS is a prospective approach in F8 mutation studies (Lindblom & Robinson, 2011). 
NGS is an alternative sequencing strategy that redefines “high-throughput sequencing”. 
These technologies outperform the older Sanger-based sequencing by throughput capacity 
and reduce the cost of sequencing. However, NGS still faces some problems in application 
to F8 or F9 sequencing for mutation identification. The cost of NGS equipment is more 
expensive than that of other capillary sequencing machines. As NGS sifts through a large 
amount of data, a bioinformatics expert is needed to analyze the high-throughput 
sequencing data. Recently, NGS companies have begun launching mini-scale (personal 
sequencing system) equipment.  
Typical examples of mini-scale NGS machines are the GS junior system from Roche, which 
is based on 454 sequencing, the MiSeq from Illumina, and the Ion torrent from Life 
Technology. These equipments can amplify 10–100 M genes with proven technology (Glenn, 
2011). Moreover, they can be applied variously to amplicon sequencing assays, small 
genome sequencing, exome sequencing, and genome-wide association study (GWAS) 
targeted regions (Grossmann et al., 2011). They also require neither bulky equipments for 
analysis nor lengthy time to produce a large amount of results. These advantages of mini-
scale sequencing are considered useful for the identification of F8 or F9 sequence variants. 
Established capillary electrophoresis requires at least 40 reactions to analyze the 26 exons in 
the F8 gene from 1 person. It would take approximately 3,840 sequencing reactions to 
survey 96 patients for the F8 mutation (Grossmann et al., 2011). This uses a lot of money and 
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is labor intensive. However, the MiSeq system and TruSeq® amplicon sequencing method 
requires just 1 sequencing reaction to carry out the task and a week to analyze F8 sequence 
variations. This prospective tool could be widely used in hemophilia diagnosis. 
5. Concluding comments 
Mutations in F8 result in truncated FVIII proteins, which can affect their interaction with 
other proteins in the coagulation cascade. Some mutations affect the recognition region of 
molecular chaperone proteins in the Golgi apparatus or endoplasmic reticulum during post-
translational modification of FVIII (Dorner et al., 1987; Lenting et al., 1998; Leyte et al., 1991). 
Another consideration of the F8 or F9 mutation is closely related with the development of 
inhibitory antibodies. For these reasons, effective profiling of mutations in F8 or F9 is 
important for the diagnosis and therapy of hemophilia, as well as prediction of inhibitor 
development.  
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